The EC approved upadacitinib for active polyarticular JIA in children 2 years and older, based on phase 1 SELECT-YOUTH efficacy and safety data.
News|Articles|January 10, 2024
Rheumatoid Arthritis Quiz: Gastrointestinal Symptoms and RA
Author(s)Ingrid Torjesen
As gastrointestinal (GI) symptoms are common in the US, how does rheumatoid arthritis (RA) affect the frequency of GI events? Test your knowledge with this quiz.
Advertisement
Is the following statement true or false?
Patients with rheumatoid arthritis have an increased risk of upper GI events but no increased risk of lower GI events compared with the general population.
Advertisement
Related to this article
August 2026 rheumatology highlights include FDA approval of brepocitinib for dermatomyositis and garetosmab-grts for FOP, and new trial data.
In RA-BRIDGE and RA-BRANCH, baricitinib failed to demonstrate VTE noninferiority in patients with RA enriched for thromboembolic risk factors.
A Phase 2a basket trial produced ACR50 responses in 71% of refractory RA patients at 6 months.
Advertisement
Advertisement